Immune System and Immune Deficiency

MEDLINE EXPRESS (R) 1991-1995 141 of 469

TI: The activities of coenzyme Q10 and vitamin B6 for immune responses.
 AU: Folkers-K; Morita-M; McRee-J Jr
SO: Biochem-Biophys-Res-Commun. 1993 May 28; 193(1): 88-92
AB: Coenzyme Q10 (CoQ10) and vitamin B6 (pyridoxine) have been administered together and separately to three groups of human subjects. The blood levels of CoQ10 increased (p < 0.001) when CoQ10 and pyridoxine were administered together and when CoQ10 was given alone. The blood levels of IgG increased when CoQ10 and pyridoxine were administered together (p < 0.01) and when CoQ10 was  administered alone (p < 0.05). The blood levels of T4-lymphocytes increased when CoQ10 and pyridoxine were administered together (p < 0.01) and separately (p < 0.001). The ratio of T4/T8 lymphocytes increased when CoQ10 and pyridoxine were administered together (p < 0.001) and separately (p < 0.05). These increases in IgG and T4-lymphocytes with CoQ10 and vitamin B6 are clinically important for trials on AIDS, other infectious diseases, and on cancer.

MEDLINE EXPRESS (R) 1991-1995 144 of 469

TI: Survival of cancer patients on therapy with coenzyme Q10.
AU: Folkers-K; Brown-R; Judy-WV; Morita-M
SO: Biochem-Biophys-Res-Commun. 1993 Apr 15; 192(1): 241-5
AB: Over ca. 25 years, assays in animal models established the hematopoietic activities of coenzyme Q's in rhesus monkeys, rabbits, poultry, and children having kwashiorkor. Surprisingly, a virus was found to cause a deficiency of CoQ9. Patients with AIDS  showed a-"striking"-clinical response to therapy with CoQ10. The macrophage potentiating activity of CoQ10 was recorded by the carbon clearance method. CoQ10 significantly increased the levels of IgG in patients. Eight new case histories of cancer patients plus two reported cases support the statement that therapy of cancer patients with CoQ10, which has no significant side effect, has allowed survival on an exploratory basis for periods of 5-15 years. These results now justify  systematic protocols.

MEDLINE EXPRESS (R) 1991-1995 160 of 469

TI: Energy transformations in the biosynthesis of the immune system: their relevance to the progression and treatment of AIDS.
AU: Tanner-HA
SO: Med-Hypotheses. 1992 Aug; 38(4): 315-21
AB: Dysfunction of the immune system is observed in diseases where metabolic respiration is inhibited. Anabolites that enhance oxidative phosphorylation will provide the ATP essential for the biosynthesis of  the cellular components and antibodies of the immune system. The induction of Coenzyme Q10 has been observed to protect against tumor growth and to enhance viral immunity in experimental animals. In a pilot study in AIDS patients the energy mediating catalyst elicited remarkable improvement. Additional cellular respiratory stimulants are considered as palliative synergists designed to enhance immunity in HIV infection. Competing antagonists to metabolic respiration acting to negate the effect of F delta in mediating optimal immune response to HIV are evaluated.

MEDLINE EXPRESS (R) 1991-1995 189 of 469

TI: Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS related complex.
AU: Folkers-K; Hanioka-T; Xia-LJ; McRee-JT Jr; Langsjoen-P
SO: Biochem-Biophys-Res-Commun. 1991 Apr 30; 176(2): 786-91
AB: Coenzyme Q10 (CoQ10) is indispensable to biochemical mechanisms of bioenergetics, and it has a non-specific role as an antioxidant. CoQ10 has shown a hematological activity for the human and has shown an influence on the host defense system. The T4/T8 ratios of lymphocytes are known to be low in patients with AIDS, ARC and malignancies. Our two patients with ARC have survived four-five years without any symptoms of adenopathy or infection on continuous treatment with CoQ10. We have newly found that 14 ordinary subjects responded to CoQ10 by increases in the T4/T8 ratios and an increase in blood levels of CoQ10; both by p less than 0.001. This knowledge and survival of two ARC patients for four-five years on CoQ10 without symptoms, and new data on increasing ratios of T4/T8 lymphocytes in the human by treatment with CoQ10 constitute a rationale for new double blind clinical trials on treating patients with AIDS, ARC and diverse malignancies with CoQ10.